Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review

Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review

The immune checkpoint inhibitor (ICI), anti-programmed cell death receptor-1 (PD-1) antibody, has gained widespread approval for treating various malignancies. Among the immune-related adverse reactions (irAEs) during ICI treatment, the lichenoid reaction is noteworthy. Sintilimab, a new PD-1 inhibi...

Full description

Bibliographic Details
Main Authors: Shuting Zhou, Zhenyu Zhang, Xiaodong Feng, Chengjian Zhao, Lu Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Pharmacology
Subjects:
lichenoid reactions
Sintilimab Therapy
immune checkpoint inhibitors (ICIs)
PD-1 inhibitor
mucocutaneous reactions
immune-related adverse events (irAEs)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1276788/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1276788/full

Similar Items